In the first-line treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC), osimertinib combined with platinum–pemetrexed has become a key regimen of clinical interest based on the outstanding results of the FLAURA2 study. The study confirmed that, compared with osimertinib monotherapy, the combination regimen significantly prolonged progression-free survival (PFS) and overall survival (OS). In the combination group, the median duration of exposure to osimertinib was 22 months longer than that of pemetrexed, indicating a prolonged chemotherapy-free period for patients. As a result, chemotherapy rechallenge has become a common subsequent treatment approach in this population.
The European Lung Cancer Congress (ELCC) 2026 was held from March 25 to 28 in Copenhagen, Denmark. As a highly influential global academic meeting in thoracic oncology, the congress brought together the latest research findings and cutting-edge advances in lung cancer diagnosis and treatment. Recently, an exploratory analysis of the FLAURA2 study (Abstract No. 27P; presenter: Carles Escriu, Liverpool, UK) was presented at the meeting, focusing on this key treatment scenario and providing important references for clinical practice. Medical World has compiled the highlights and invited Prof. Bo Zhang from Shanghai Chest Hospital for in-depth interpretation.
Major Data from the FLAURA2 Exploratory Analysis: Platinum-Based Chemotherapy Rechallenge Achieves a 77% 3-Year OS Rate
Study Background
The phase III, global, open-label FLAURA2 study (NCT04035486) has confirmed that for patients with advanced EGFR-mutant NSCLC, first-line osimertinib combined with platinum–pemetrexed significantly improves PFS and OS compared with osimertinib monotherapy. This analysis aimed to provide a descriptive summary of chemotherapy rechallenge data to inform subsequent treatment decisions in clinical practice.
Methods
The study enrolled previously untreated patients with advanced NSCLC harboring EGFR mutations (exon 19 deletion or exon 21 L858R point mutation). Eligible patients had a World Health Organization (WHO) performance status of 0 or 1 (stable central nervous system metastases were allowed). Patients were randomized 1:1 into two groups:
- Combination group: osimertinib (80 mg once daily) plus platinum–pemetrexed (every 3 weeks for 4 cycles), followed by maintenance therapy with osimertinib plus pemetrexed;
- Monotherapy group: osimertinib alone (80 mg once daily).
Treatment continued until disease progression or discontinuation. The primary endpoint was PFS assessed by investigators according to RECIST 1.1 criteria, and the key secondary endpoint was OS. This analysis retrospectively evaluated the first subsequent treatment among patients who discontinued first-line therapy due to disease progression. The data cutoff date was June 12, 2025.
Results
Overall, among patients who discontinued first-line treatment due to disease progression, 88 of 127 patients (69%) in the combination group and 143 of 185 patients (77%) in the monotherapy group received first subsequent treatment.
Specifically, in the combination group, among the 88 patients who received first subsequent treatment, 65 (74%) received chemotherapy-containing regimens, including 39 (44%) who received platinum-based chemotherapy and 26 (30%) who received non-platinum chemotherapy. In addition, 17 patients (19%) received pemetrexed-containing regimens as first subsequent treatment, with a median pemetrexed-free interval of 19.8 months (range: 0.5–42.3 months).
In the monotherapy group, among the 143 patients who received first subsequent treatment, 103 (72%) received platinum-based chemotherapy as first subsequent treatment.
Further details regarding first subsequent chemotherapy regimens, chemotherapy-free intervals, and the duration of pemetrexed use in first-line and subsequent treatment will be presented at the meeting. The OS data according to different first subsequent treatment approaches are shown in the table.
Table: Comparison of 3-Year Overall Survival Rates According to Different First Treatment Approaches
|
FST |
OS events/pts, n |
3-yr OS, % (95% CI)* |
|
Discontinued 1L osi + plat–pem due to PD |
||
|
Plat chemo |
22/39 |
77 (60, 87) |
|
Non-plat chemo |
25/26 |
27 (12, 44) |
|
Other Tx† |
12/23 |
65 (42, 81) |
|
Discontinued 1L osi mono due to PD |
||
|
Plat chemo |
77/103 |
42 (33, 52) |
|
Other Tx†‡ |
27/40 |
60 (43, 73) |
Note: Baseline characteristics were generally well balanced between FST subgroups. *Kaplan–Meier estimated. †Includes EGFR targeted therapies, new investigational agents, and new modalities such as antibody-drug conjugates. ‡Includes 5 pts who had non-plat chemo as FST; as the sample size was too small for a standalone analysis, these pts were included in the ‘other Tx’ category for the osi mono group. CI, confidence interval.
Conclusion
After progression on first-line osimertinib plus platinum–pemetrexed, chemotherapy rechallenge is a common subsequent treatment option, which may be associated with the prolonged chemotherapy-free interval provided by the regimen. Notably, patients who received platinum-based chemotherapy rechallenge after progression on combination therapy achieved a 3-year OS rate of up to 77%, providing important clinical direction for subsequent treatment strategies in this population.
Clinical Interpretation: Core Value and Clinical Implications of the FLAURA2 Exploratory Analysis
For oncologists, selecting subsequent treatment after progression on first-line targeted combination therapy in advanced EGFR-mutant NSCLC has always been a key and challenging issue in clinical practice. This exploratory analysis of the FLAURA2 study focuses on the efficacy and patterns of chemotherapy rechallenge after progression on osimertinib plus platinum–pemetrexed, providing highly valuable evidence-based guidance for clinical decision-making. Its core significance is reflected in three dimensions.
First, this analysis clarifies the clinical feasibility and commonality of chemotherapy rechallenge after progression on combination therapy. EGFR-TKI combined with chemotherapy has become an important first-line option for advanced EGFR-mutant NSCLC; however, treatment strategies after progression remain insufficiently defined, and the applicability of chemotherapy rechallenge has long been debated. This study showed that 69% of patients in the combination group who experienced progression received first subsequent treatment, of whom 74% received chemotherapy-containing regimens and 44% received platinum-based chemotherapy. These data confirm that chemotherapy rechallenge is one of the mainstream options after progression on combination therapy, providing practical support for clinical application.
Second, key survival data provide precise guidance for selecting chemotherapy rechallenge strategies. Most clinically significant is that patients who received platinum-based chemotherapy rechallenge after progression on combination therapy achieved a 3-year OS rate of 77%, superior to 27% in the non-platinum chemotherapy group and 42% in patients from the monotherapy group who received platinum-based chemotherapy after progression. These findings suggest that platinum-based chemotherapy rechallenge should be considered a preferred option after progression on combination therapy. The favorable long-term survival benefit may be closely related to the median pemetrexed-free interval of 19.8 months achieved with combination therapy—a prolonged chemotherapy-free interval may reduce tumor resistance and restore tumor sensitivity to chemotherapy. This finding is consistent with the overall survival advantage observed in the final results of FLAURA2.
Finally, this analysis provides important reference for individualized treatment in clinical practice. In the combination group, 19% of patients received pemetrexed-containing regimens as subsequent treatment, suggesting the feasibility of pemetrexed rechallenge, particularly for patients who derived significant benefit from first-line therapy without notable chemotherapy-related toxicity, in whom continuation of pemetrexed may be considered. This study further enriches treatment strategies after EGFR resistance and complements emerging novel therapies.
In addition, it should be emphasized that when implementing chemotherapy rechallenge in clinical practice, careful attention must be paid to toxicity management. Patients differ in their tolerance to platinum agents and pemetrexed, and dose adjustments or extended dosing intervals should be considered based on prior treatment-related toxicities, current performance status, and organ function, balancing efficacy and safety. Particularly in patients from the combination group who have previously received platinum–pemetrexed in the first-line setting, vigilance regarding cumulative toxicity is required, and refined management strategies are essential to maximize patient benefit.
In summary, this exploratory analysis of FLAURA2 fills a research gap regarding chemotherapy rechallenge after progression on first-line combination therapy in advanced EGFR-mutant NSCLC, confirming the favorable efficacy and clinical role of platinum-based chemotherapy rechallenge. In clinical practice, for patients progressing on first-line osimertinib plus platinum–pemetrexed, platinum-based chemotherapy rechallenge may be considered, with individualized treatment strategies developed based on performance status, prior treatment-related toxicity, and genomic testing results to maximize survival benefit.
Reference:
[1] 27P - Chemotherapy rechallenge in patients with EGFR-mutated advanced NSCLC who discontinued 1L osimertinib + platinum–pemetrexed due to progression: FLAURA2 exploratory analysis.Posters and ePosters - ELCC 2026 Onsite and Online Congress